Bdsi Drug Patent Portfolio

Bdsi owns 3 orange book drugs protected by 13 US patents Given below is the list of Bdsi's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9522188 Abuse resistant transmucosal drug delivery device 24 Apr, 2035
Active
US10952968 Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives 13 May, 2033
Active
US9901539 Transmucosal drug delivery devices for use in chronic pain relief 21 Dec, 2032
Active
US8703177 Abuse-resistant mucoadhesive devices for delivery of buprenorphine 20 Aug, 2032
Active
US9108975 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same 11 Nov, 2031
Active
US8084460 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 11 Jan, 2028
Active
USRE46365 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 11 Jan, 2028
Active
US8147866 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
Active
US9655843 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
Active
US8536192 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 05 Oct, 2026
Active
USRE46375 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 05 Oct, 2026
Active
US7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces 22 Jan, 2020 Expired
US6159498 Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces 18 Oct, 2016 Expired


Given below is the list of recent legal activities going on the following drug patents of Bdsi.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 20 Jun, 2024 US9522188
Payment of Maintenance Fee, 12th Year, Large Entity 03 Oct, 2023 US8147866 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 03 Oct, 2023 US8147866 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 01 Feb, 2023 US9108975
Payment of Maintenance Fee, 8th Year, Large Entity 22 Oct, 2021 US8703177 (Litigated)
Expire Patent 27 Sep, 2021 US7579019 (Litigated)
Expire Patent 27 Sep, 2021 US7579019 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 27 Aug, 2021 US9901539
Maintenance Fee Reminder Mailed 12 Apr, 2021 US7579019 (Litigated)
Maintenance Fee Reminder Mailed 12 Apr, 2021 US7579019 (Litigated)
Recordation of Patent Grant Mailed 23 Mar, 2021 US10952968
Patent Issue Date Used in PTA Calculation 23 Mar, 2021 US10952968
Email Notification 05 Mar, 2021 US10952968
Issue Notification Mailed 03 Mar, 2021 US10952968
Email Notification 18 Feb, 2021 US10952968


Bdsi's Drug Patent Litigations

Bdsi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 22, 2014, against patent number US7579019. The petitioner MONOSOL RX, LLC, challenged the validity of this patent, with Arius Two, Inc. as the respondent. Click below to track the latest information on how companies are challenging Bdsi's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9522188 December, 2012 Decision
(29 Jan, 2016)
Andrew Finn et al
US7579019 January, 2014 FWD Entered
(05 Aug, 2015)
Arius Two, Inc. MONOSOL RX, LLC


Bdsi's Family Patents

Bdsi drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 29.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Bdsi Drug List

Given below is the complete list of Bdsi's drugs and the patents protecting them.


1. Belbuca

Belbuca is protected by 5 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9901539 Transmucosal drug delivery devices for use in chronic pain relief 21 Dec, 2032
(8 years from now)
Active
US8147866 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
(2 years from now)
Active
US9655843 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
(2 years from now)
Active
US7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces 22 Jan, 2020
(4 years ago)
Expired
US6159498 Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces 18 Oct, 2016
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belbuca's drug page


2. Bunavail

Bunavail is protected by 6 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9522188 Abuse resistant transmucosal drug delivery device 24 Apr, 2035
(10 years from now)
Active
US8703177 Abuse-resistant mucoadhesive devices for delivery of buprenorphine 20 Aug, 2032
(7 years from now)
Active
US8147866 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
(2 years from now)
Active
US9655843 Transmucosal delivery devices with enhanced uptake 23 Jul, 2027
(2 years from now)
Active
US7579019 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces 22 Jan, 2020
(4 years ago)
Expired
US6159498 Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces 18 Oct, 2016
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bunavail's drug page


3. Symproic

Symproic is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10952968 Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives 13 May, 2033
(8 years from now)
Active
US9108975 Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same 11 Nov, 2031
(7 years from now)
Active
US8084460 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 11 Jan, 2028
(3 years from now)
Active
USRE46365 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 11 Jan, 2028
(3 years from now)
Active
US8536192 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 05 Oct, 2026
(1 year, 11 months from now)
Active
USRE46375 6,7-unsaturated-7-carbamoyl substituted morphinan derivative 05 Oct, 2026
(1 year, 11 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Symproic's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List